Skip to Main Content

Paper Details

Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results.
Am J Hematol
88
2018
Author NameAffiliation
Jorge CortesUniversity of Texas, MD Anderson Cancer Center
Vivian G OehlerFred Hutchinson Cancer Research Center
Daniel J DeAngeloDana-Farber Cancer Institute and Harvard Medical School
Daniel A PollyeaUniversity of Colorado School of Medicine
  • 1 - 4

Datasets

Release 1.2